Synthetic Cannabinoids and Its Association With Persistent Negative Symptoms of Schizophrenia

  • Satodiya R
  • Palekar N
N/ACitations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Schizophrenia has a multidomain symptom cluster, including positive, negative, and cognitive symptoms. Synthetic cannabinoids (SC) commonly perpetuate the positive symptoms of schizophrenia. We present a case of predominant negative symptoms following the use of SC even though our patient had a consistent history of experiencing positive symptoms in the past. The hypoactive dopaminergic system in the prefrontal cortex can induce negative symptoms in schizophrenia. However, the modulating properties of SC on cannabinoid receptors can feed into the negative symptom progression. The psychoactive properties of SC need further research to understand its clinical characteristics.

Cite

CITATION STYLE

APA

Satodiya, R., & Palekar, N. (2020). Synthetic Cannabinoids and Its Association With Persistent Negative Symptoms of Schizophrenia. Cureus. https://doi.org/10.7759/cureus.10329

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free